SOFT
Clinical Trial Program
A phase III trial evaluating the role of ovarian function suppression and exemestane as adjuvant therapies for premenopausal women with endocrine-responsive Breast Cancer
Phase III
Status
Follow up
Tumour subtype:
HR+
Scenario
Adjuvant
SPONSOR
PRINCIPAL INVESTIGATORS
Prue Francis, MD (Meter MacCallum Cancer Institute)
Gini Fleming, MD (University of Chicago Medical Center)
Sites
